# Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use

**Authors:** Nicoleta Mirela Blebea, Andreea Iulia Pricopie, Robert-Alexandru Vlad, Gabriel Hancu

PMC · DOI: 10.3390/ijms25084204 · International Journal of Molecular Sciences · 2024-04-10

## TL;DR

This review explores the diverse pharmacological effects of phytocannabinoids from the Cannabis plant and their potential for therapeutic use.

## Contribution

The paper provides a comprehensive overview of the pharmacological profiles and therapeutic potential of various phytocannabinoids beyond CBD and THC.

## Key findings

- CBD shows anti-inflammatory, neuroprotective, and anxiolytic properties without psychoactive effects.
- THC has analgesic and antiemetic properties despite its psychoactive nature.
- Other phytocannabinoids like CBC, CBG, and CBN also exhibit promising pharmacological effects.

## Abstract

Phytocannabinoids, a diverse group of naturally occurring compounds extracted from the Cannabis plant, have attracted interest due to their potential pharmacological effects and medicinal uses. This comprehensive review presents the intricate pharmacological profiles of phytocannabinoids while exploring the diverse impacts these substances have on biological systems. From the more than one hundred cannabinoids which were identified in the Cannabis plant so far, cannabidiol (CBD) and tetrahydrocannabinol (THC) are two of the most extensively studied phytocannabinoids. CBD is a non-psychoactive compound, which exhibits potential anti-inflammatory, neuroprotective, and anxiolytic properties, making it a promising candidate for a wide array of medical conditions. THC, known for its psychoactive effects, possesses analgesic and antiemetic properties, contributing to its therapeutic potential. In addition to THC and CBD, a wide range of additional phytocannabinoids have shown intriguing pharmacological effects, including cannabichromene (CBC), cannabigerol (CBG), and cannabinol (CBN). The endocannabinoid system, made up of the enzymes involved in the production and breakdown of endocannabinoids, cannabinoid receptors (CB1 and CB2), and endogenous ligands (endocannabinoids), is essential for preserving homeostasis in several physiological processes. Beyond their effects on the endocannabinoid system, phytocannabinoids are studied for their ability to modify ion channels, neurotransmitter receptors, and anti-oxidative pathways. The complex interaction between phytocannabinoids and biological systems offers hope for novel treatment approaches and lays the groundwork for further developments in the field of cannabinoid-based medicine. This review summarizes the state of the field, points out information gaps, and emphasizes the need for more studies to fully realize the therapeutic potential of phytocannabinoids.

## Linked entities

- **Chemicals:** cannabidiol (PubChem CID 644019), tetrahydrocannabinol (PubChem CID 16078), cannabichromene (PubChem CID 30219), cannabigerol (PubChem CID 5315659), cannabinol (PubChem CID 2543)
- **Species:** Cannabis (taxon 3482)

## Full-text entities

- **Genes:** CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, CNR2 (cannabinoid receptor 2) [NCBI Gene 1269] {aka CB-2, CB2, CX5}
- **Diseases:** inflammatory (MESH:D007249)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11050509/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11050509/full.md

## References

99 references — full list in the complete paper: https://tomesphere.com/paper/PMC11050509/full.md

---
Source: https://tomesphere.com/paper/PMC11050509